Hydrogel repairs damaged cardiac tissue

The gel is injected through a catheter without requiring surgery or general anesthesia.

The results of the study were published in Science Translational Medicine and clear the way for clinical trials to begin this year in Europe.

According to UCSD, there are an estimated 785,000 new heart attack cases in the United States each year, with no established treatment for repairing the resulting damage to cardiac tissue.

Lead researcher Karen Christman, a professor in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering, said the gel forms a scaffold in damaged areas of the heart, encouraging new cell growth and repair.

Because the gel is made from heart tissue taken from pigs, the damaged heart responds positively, creating a harmonious environment for rebuilding, rather than setting off a chain of adverse immune system defenses.

‘While more people today are initially surviving heart attacks, many will eventually go into heart failure,’ said Christman in a statement. ‘Our data show that this hydrogel can increase cardiac muscle and reduce scar tissue in the region damaged by the heart attack, which prevents heart failure. These results suggest this may be a novel minimally invasive therapy to prevent heart failure after a heart attack in humans.’

The hydrogel is made from cardiac connective tissue that is stripped of heart muscle cells through a cleansing process, freeze-dried and milled into powder form, and then liquefied into a fluid that can be easily injected into the heart.

Once it hits body temperature, the liquid turns into a semi-solid, porous gel that encourages cells to repopulate areas of damaged cardiac tissue and to improve heart function, said Christman.

The material is also biocompatible; animals treated with the hydrogel are said to have suffered no adverse affects such as inflammation, lesions or arrhythmic heart beating.

Further tests with human blood samples showed that the gel had no effect on the blood’s clotting ability, which underscores the biocompatibility of the treatment for use in humans.

San Diego-based startup, Ventrix, Inc, which Christman co-founded, has licensed the technology for development and commercialisation.